Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

May 23, 2022, 8:00 a.m. EDT

ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Immunogen Inc. (IMGN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of ImmunoGen Inc. /zigman2/quotes/208003500/composite IMGN +4.08% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer treatment. The mirvetuximab soravtansine monotherapy has a Prescription Drug User Fee Act action date of Nov. 28. ImmuoGen said it is still enrolling patients in a confirmatory trial, with plans to announce data from that study early next year. The company's stock has declined 51.7% this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.37% is down 18.1%.

/zigman2/quotes/208003500/composite
US : U.S.: Nasdaq
$ 5.10
+0.20 +4.08%
Volume: 2.02M
July 6, 2022 11:30a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.08 billion
Rev. per Employee
$870,076
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,817.19
-14.20 -0.37%
Volume: 705.81M
July 6, 2022 11:30a
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.